Sutro Biopharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Sutro Biopharma

09/05/2025 13:31

Sutro Biopharma Inc STRO.OQ STRO.O is expected to show a fall in quarterly revenue when it reports  results  for the period ending June 30 2025

The South San Francisco California-based  company is expected to report a 51.2% decrease in revenue to $12.544 million from $25.71 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of 49 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 17.1% in the last three months. ​

Wall Street's median 12-month price target for Sutro Biopharma Inc is $3.00​, above​ its last closing price of $0.96. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.70
-0.71
-0.91
Missed
-28.6
Dec. 31 2025
-0.78
-0.83
-0.89
Missed
-7.1
Sep. 30 2024
-0.73
-0.73
-0.59
Beat
19.7​
Jun. 30 2024
-0.76
-0.79
-0.59
Beat
25.5
​​Mar. 31 2024
-0.88
-0.92
-0.95
Missed
-3
Dec. 31 2023
-0.82
0.52
Beat
163.2​
Sep. 30 2023
-0.74
-0.74
-0.81
Missed
-10.1
Jun. 30 2023
-0.75
-0.73
-0.64
Beat
12.6

This summary was machine generated May 9 at 12:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)